Ebola Virus’s Glycoproteins and Entry Mechanism

Khataby, Khadija; Kasmi, Yassine; Hammou, Rahma Ait; Laasri, FatimaEzzahra; Boughribi, Said; Ennaji, My Mustapha

doi:10.5772/64032

Cited by 5 publications

(7 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…the small secretary glycoprotein neutralizes the host cell neutrophils through CD16b and resulting in lymphocyte death and further vascular dysregulation [52].…”

Section: Small Secreted Glycoprotein Of Ebovmentioning

confidence: 99%

Ebola, the Negative Stranded RNA Virus

Farman¹,

Badshah²,

Khan³

et al. 2021

Some RNA Viruses

View full text Add to dashboard Cite

Ebola virus (EBV) is a deadly virus that has resulted in a number of deaths during its outbreaks in Africa in 2014–2016 and 2018–2019. This virus causes a hemorrhagic fever like other pathogenic viruses of the Filoviridae family with high mortality rate. The exact reservoir of the ebola virus is not known, but different mammal groups are the source from which it is transferred to the human population. The transmission among the human population is through body fluids of patients and also through aersol droplets in the air. The role of different glycoproteins in the budding formation has helped a lot in understanding the physiology of the ebola virus. Most of these viral glycoproteins synthesis and the replication enzymes offer a good inhibitory target for drug design against the ebola virus. Recently, different groups have claimed the development of a successful vaccine for the ebola virus. However, the availability of the vaccines to the poor population of Africa and other parts of the world is still not practical.

show abstract

“…the small secretary glycoprotein neutralizes the host cell neutrophils through CD16b and resulting in lymphocyte death and further vascular dysregulation [52].…”

Section: Small Secreted Glycoprotein Of Ebovmentioning

confidence: 99%

Ebola, the Negative Stranded RNA Virus

Farman¹,

Badshah²,

Khan³

et al. 2021

Some RNA Viruses

View full text Add to dashboard Cite

show abstract

“…The MLD is found on the variable region of GP 1 (C-terminal) and increases the permeability of EBOV into the blood vessels, and also masks the cell from the innate immune response by obstructing access to the epitope of GP [117,118]. MLD can also shield the cellular surface protein sterically, causing cell damage, leakage of an explanted blood vessel, rounding and detachment of cell, and loss of physiological functions [119,120,121].…”

Section: Ebov Gp: Bane or Benefitmentioning

confidence: 99%

“…There are four members of CLECs that have been identified as Ebola GP receptors, namely, CLEC4G/LSECtin, dendritic cell-specific ICAM-3-grabbing non-integrin (DC-SIGN), liver/lymph node-specific ICAM-3 grabbing non-integrin (L-SIGN), asialoglycoprotein receptor 1 (ASGPRI) and human macrophage galactose- and acetylgalactosamine-specific C-type lectin (hMGL) [147,148]. CLECs are on the liver, alveolar macrophages, and epithelial cells [117,149,150]. Besides, the expressions of Nieman-Pick C1 (NPC1), integrin αV, and Mer have been reported to be essential for the infection of macrophages by EBOV GP.…”

Section: Ebov Gp’s Affinity For Dendritic Cells and Macrophages Inmentioning

confidence: 99%

“…The efficacy of VSV–EBOV has been demonstrated in cynomolgus macaques to give 100% protection [21]. Also, human phase 1–3 trials have revealed the effectiveness of VSV–EBOV GP in inducing an immune response against EBOV [100,117]. Thus, EBOV GP infused with a specific viral antigenic protein can be incorporated into VSV as a vector-based vaccine (Figure 1C) to induce stronger and more robust immune responses against the specific virus [116].…”

Section: Ebola Gp-targeting Dcs Can Facilitate Immune Responses Fomentioning

confidence: 99%

See 1 more Smart Citation

Dendritic Cells/Macrophages-Targeting Feature of Ebola Glycoprotein and its Potential as Immunological Facilitator for Antiviral Vaccine Approach

Olukitibi

Mahmoudi

et al. 2019

Microorganisms

View full text Add to dashboard Cite

In the prevention of epidemic and pandemic viral infection, the use of the antiviral vaccine has been the most successful biotechnological and biomedical approach. In recent times, vaccine development studies have focused on recruiting and targeting immunogens to dendritic cells (DCs) and macrophages to induce innate and adaptive immune responses. Interestingly, Ebola virus (EBOV) glycoprotein (GP) has a strong binding affinity with DCs and macrophages. Shreds of evidence have also shown that the interaction between EBOV GP with DCs and macrophages leads to massive recruitment of DCs and macrophages capable of regulating innate and adaptive immune responses. Therefore, studies for the development of vaccine can utilize the affinity between EBOV GP and DCs/macrophages as a novel immunological approach to induce both innate and acquired immune responses. In this review, we will discuss the unique features of EBOV GP to target the DC, and its potential to elicit strong immune responses while targeting DCs/macrophages. This review hopes to suggest and stimulate thoughts of developing a stronger and effective DC-targeting vaccine for diverse virus infection using EBOV GP.

show abstract

“…The viral RNA contains information about eight proteins: VP24, VP30, VP35, VP40, L, NP, sGP and GP1/2. Each of the protein expressed is known for its multi-functionality, essentially VP35 and GP that present multi-functionality in the pathogenesis process and in the inhibition of immune responses in the host [8]. The only virally expressed protein on the virion surface of EBOV is the glycoprotein (GP) that is critical for attachment to host cells and catalysis of membrane fusion [9].…”

Section: Introductionmentioning

confidence: 99%

Immunoglobulin G Specific Antibody Level against Ebola Viral Glycoprotein and Nucleoprotein in Ebola Virus Disease Survivors and Their Relatives

Mafopa¹,

Wadoum²,

Giovanetti³

et al. 2021

JBM

View full text Add to dashboard Cite

Ebola virus disease is a complex zoonosis that is highly virulent in humans. Despite its sorely pathogenic and lethal nature, survivors of this infection and even asymptomatic cases are able to develop both humoral and cellular immunity against several Ebola virus (EBOV) proteins. We aimed at determining immunoglobulin G (IgG) antibodies level against two Ebola viral antigens, the glycoprotein and the nucleoprotein in Ebola survivors and their relatives. Anti-EBOV glycoprotein (GP) and nucleoprotein (NP) IgG antibodies were quantified using ELISA. We enrolled 199 participants in two different sites as follow: 91 survivors at the Loreto clinic and 70 survivors with 38 relatives of Sierra Leone Association of Ebola Survivors Bombali Branch (SLAESB) tested for anti-EBOV NP and anti-EBOV GP IgG antibodies. Our findings revealed that the median anti-EBOV IgG level among survivors was 5.7128

show abstract

Ebola Virus’s Glycoproteins and Entry Mechanism

Cited by 5 publications

References 41 publications

Ebola, the Negative Stranded RNA Virus

Ebola, the Negative Stranded RNA Virus

Dendritic Cells/Macrophages-Targeting Feature of Ebola Glycoprotein and its Potential as Immunological Facilitator for Antiviral Vaccine Approach

Immunoglobulin G Specific Antibody Level against Ebola Viral Glycoprotein and Nucleoprotein in Ebola Virus Disease Survivors and Their Relatives

Contact Info

Product

Resources

About